HIF1A and B-cell chronic lymphocytic leukemia: In conclusion, our work suggests that pharmacological strategies aimed at inhibiting HIF-1α may be of added value for CLL therapy, and further studies should be performed to evaluate the efficacy of these compounds in settings that recapitulate drug-resistant disease for future clinical development.